NIH's Long COVID Treatment Trials Are Finally Moving Forward—Here's What's Being Tested

After years of uncertainty, the National Institutes of Health (NIH) is launching the first federally coordinated clinical trials specifically designed to treat Long COVID. The NIH RECOVER-Treating Long COVID (RECOVER-TLC) initiative has moved beyond research planning and into active recruitment, testing multiple treatment approaches that could help millions of people still struggling with persistent symptoms months or years after their initial COVID-19 infection.

What Treatment Strategies Are Being Tested in RECOVER-TLC?

The RECOVER-TLC program is advancing four distinct treatment strategies, though most are still in early phases. The selection process began with nearly 600 proposed therapies—including medications, devices, and behavioral interventions—submitted through an open portal managed by the Foundation for the National Institutes of Health. Multidisciplinary working groups that include researchers, clinicians, federal agency representatives (including the Food and Drug Administration (FDA) and National Institute of Allergy and Infectious Diseases (NIAID)), and patient advocates review each proposal to determine which treatments warrant clinical testing.

The rigorous review structure increases scientific credibility but also extends timelines. Selected treatments must move through a structured process that includes protocol drafting, public comment periods, protocol revision, Institutional Review Board (IRB) approval, site selection and staff training, participant recruitment, and data collection and analysis.

Which Long COVID Trials Are Recruiting Patients Now?

Currently, only one RECOVER-TLC trial is actively recruiting participants: a study testing baricitinib, a medication that belongs to a class of drugs called JAK inhibitors. Baricitinib works by reducing pro-inflammatory cytokine signaling—essentially dampening the overactive immune response that may underlie Long COVID symptoms. The trial is testing a dose of 4 milligrams daily for 24 weeks in a randomized, placebo-controlled design, meaning some participants receive the active drug while others receive a placebo to ensure results reflect the medication's true effects.

The primary outcomes being measured are neurocognitive and neuropsychiatric function—in other words, improvements in thinking, memory, mood, and mental clarity. Secondary outcomes include exercise capacity and quality of life, recognizing that Long COVID affects multiple body systems.

A second trial testing low-dose naltrexone (LDN) for Long COVID pain and fatigue is also in development, though it has not yet begun recruiting. This treatment targets a different mechanism, potentially helping with the widespread pain and exhaustion that characterize Long COVID for many patients.

How to Participate in Long COVID Clinical Trials

• Check Eligibility Requirements: Each trial has specific inclusion and exclusion criteria based on symptom severity, duration of illness, and other health factors. Review the trial protocol carefully to determine if you qualify.
• Understand the Commitment: Clinical trials require multiple visits, regular assessments, and adherence to study protocols. The baricitinib trial, for example, involves 24 weeks of daily medication and scheduled follow-up appointments.
• Review Informed Consent Documents: Before enrolling, you'll receive detailed information about potential risks, benefits, and your rights as a study participant. Take time to ask questions and ensure you understand what participation involves.
• Contact Your Local Research Site: The RECOVER-TLC initiative operates through multiple clinical sites across the United States. Your healthcare provider can help you find a participating site or you can search the NIH clinical trials database.

Why Does Long COVID Need Federally Coordinated Trials?

Long COVID remains poorly understood, with no FDA-approved treatments and no consensus on the best therapeutic approach. The condition affects an estimated 7.7 million Americans, causing persistent symptoms including cognitive dysfunction, fatigue, breathing problems, and cardiovascular issues that can last months or years after the acute infection resolves. By coordinating multiple trials through a single federal framework, the RECOVER-TLC initiative aims to accelerate the discovery of effective treatments while maintaining scientific rigor and transparency.

The multidisciplinary review process—which includes input from patient advocates alongside researchers and regulators—ensures that treatments being tested address the symptoms that matter most to people living with Long COVID. This patient-centered approach represents a shift in how clinical research is conducted, moving beyond traditional models where researchers alone determine which outcomes to measure.

What's the Timeline for Results?

As of early 2026, the baricitinib trial is the only RECOVER-TLC study currently recruiting participants, while other treatment candidates remain in protocol preparation or early recruitment phases. The extended timeline reflects the complexity of conducting rigorous, federally coordinated clinical trials. However, this deliberate pace also means that when results do emerge, they will carry substantial weight in guiding clinical practice and FDA approval decisions.

For the millions of people with Long COVID seeking answers, these trials represent a critical turning point. Rather than relying on anecdotal reports or off-label use of medications, patients and clinicians will soon have evidence-based treatment options grounded in randomized controlled trials—the gold standard of medical research.